FDA nod for Teva's new asthma treatments

31 January 2017

Teva Pharmaceutical Industries (NYSE: TEVA) has received US Food and Drug Administration own branded versions of two asthma treatments sold by UK pharma major GlaxoSmithKline (LSE: GSK).

The Israeli drugmaker has gained approval for the AirDuo RespiClick (fluticasone/salmeterol), which has the same active phamaceutical ingredients (APIs) as GSK's Advair, and ArmonAir RespiClick (fluticasone), with the same APIs as the Flovent product. These treatments are now expected to be launched in the USA later this year.

"We will provide physicians and their patients with additional treatment options in an inhaler device that does not require hand-breath coordination during inhalation"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK